Aortyx, a spin-off of Institut Químic de Sarrià and Hospital Clinic Barcelona that is developing an innovative patch for minimally invasive treatment of aortic dissections, has closed its second round of funding for €2.4 million through acrowdequity campaign on Capital Cell. CataloniaBio & Healthtech, which Aortyx is a member of, announced the round in early March.

This round brought in Medex Partners, Vergara Capital and several family offices as new shareholders. 

The financial resources will go to kick off pilot clinical trials in patients scheduled for 2022.

Between capital and competitive grants, Aortyx has raised nearly €5 million since 2018.

Plus, Aortyx has just been accepted into the first Medlim programme promoted by Medtronic, the Belgian fund IMEC and the Dutch government agency LIOF to shorten time to market and minimise product development mistakes.

Photo: Salvador Borrós, Vicenç Riambau, Jordi Martorell and Noemí Balà, founders of Aortyx - © Aortyx

You may also be interested in:

• Aortyx opens €1.6-million round to fund patch for healing aortic dissections
• Aortyx closes €650,000 round of funding led by Genesis Ventures
• Aortyx awarded Neotec grant for €250,000

Want to learn more about what Aortyx does? We recommend this video of CataloniaBio & HealthTech: